Compared to anti-PSMA antibodies, small-molecule PSMA inhibitors have similarly accurate localization of PCa lesions but faster tumor uptake and more rapid excretion, which reduces radiation exposure. The gene discussed is FOLH1; the disease is posterior cortical atrophy.